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Nod1 is a member of family of intracellular proteins that mediate host recognition of 
bacterial peptidoglycan. To characterize immune responses mediated by Nod1, synthetic 
ligand compounds possessing enhanced ability to stimulate Nod1 were developed to study 
the function of Nod1. Stimulation of epithelial cells with Nod1 stimulatory molecules 
induced chemokines and other proinfl ammatory molecules that are important for innate 
immune responses and recruitment of acute infl ammatory cells. Administration of Nod1 
ligands into mice induced chemokines and recruitment of acute infl ammatory cells, an 
activity that was abolished in Nod1-null mice. Microarray analysis revealed that Nod1 
stimulation induces a restricted number of genes in intestinal epithelial cells compared 
with that induced by tumor necrosis factor (TNF) 𝛂. Nod1 stimulation did not induce TNF𝛂, 
interleukin 12, and interferon 𝛄, suggesting that the primary role of Nod1 is to induce the 
recruitment of immune cells. These results indicate that Nod1 functions as a pathogen 
recognition molecule to induce expression of molecules involved in the early stages of the 
innate immune response.
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Recognition of bacterial components by host-
specifi c molecules is the fi rst step in the defense 
against invading bacteria (1). In the initial en-
counter with pathogenic bacteria, epithelial sur-
faces provide a physical barrier but also produce 
several molecules that are microbicidal or that 
inhibit bacterial growth (1). A second line of de-
fense is mediated through host cellular receptors 
that recognize molecules uniquely expressed by 
bacteria, and upon activation they induce innate 
and adaptive immune responses to eff ectively 
eliminate the invading microbe. Toll-like recep-
tors (TLRs) are a major class of host molecules 
that are activated by microbial products, includ-
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ing LPS, lipoproteins, and bacterial DNA (1, 2). 
In addition to TLRs that recognize bacterial 
ligands at the plasma membrane and luminal 
side of intracellular vesicles, a family of proteins 
called Nods, or Caterpiller, provide sensing of 
bacteria in the cytosol (2–4). The Nod protein 
family is comprises more than 20 members, in-
cluding Nod1, Nod2, Cryopyrin, and Ipaf. The 
majority of Nod proteins are composed of an 
amino-terminal eff ector domain involved in 
downstream signaling, a centrally located nu-
cleotide-binding oligomerization domain, and 
carboxyl-terminal leucine -rich repeats.
Nod1 is the founding member of the Nod 
protein family, which is expressed in multiple 
tissues and cells, including intestinal epithelia 
(2, 5). The core structure of the ligand recognized 
by Nod1 is a peptidoglycan (PGN)-specifi c 
 dipeptide, γ-d-glutamyl-meso-diaminopimelic 
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acid (iE-DAP), which exists as insoluble PGN, soluble PGN 
fragments, and intermediates produced during PGN biosyn-
thesis (6, 7). There is evidence that Nod1 mediates host rec-
ognition of bacteria or bacterial fractions containing soluble 
PGN-related molecules with the essential iE-DAP dipeptide 
(8–12). Upon recognition of its bacterial ligand, Nod1 in-
duces activation of NF-κB and mitogen-activated protein 
 kinase, two signaling pathways that are involved in cellular re-
sponses against bac teria (5–13). Activation of intracellular sig-
naling through Nod1 is mediated by RICK, a caspase recruitment 
domain– containing kinase that interacts with Nod1 (5, 13–15). 
However, the immune responses elicited by Nod1 stimula-
tion are poorly characterized.
Bacteria containing Nod1 stimulatory molecules also pos-
sess TLR ligands, including LPS, that induce innate immune 
responses in host cells (1). There is evidence that Nod and 
TLR proteins act cooperatively to modulate immune re-
sponses against bacteria. For example, stimulation of Nod1 
alone induces the secretion of very low levels of IL-6 and 
TNFα in macrophages, but the response is greatly enhanced 
by co-stimulation with LPS (6). Recent reports also suggest 
that Nod1 plays a role in intestinal immunity by regulating 
innate immune responses of epithelial cells infected with 
invasive enterobacteria and Helicobacter pylori (10, 11). The 
intestinal lumen contains a large number of resident bacte-
ria that live in a symbiotic relationship with the host (16). 
Commensal bacteria express a wide array of stimulatory 
TLR ligands, but the organism has developed mechanisms 
to avoid innate recognition and harmful infl ammatory re-
sponses at intestinal sites (17). These include a lack or low 
levels of TLRs such as TLR2 and TLR4 in intestinal epi-
thelial cells and expression of molecules that inhibit TLR 
signaling (17). Given that Nod1 is functionally expressed 
in intestinal epithelial cells (5, 9, 10, 18), we hypothesized 
that stimulation of Nod1 by bacterial products might be 
suffi  cient to induce immune responses that are important 
for host defense against invading bacteria. In this paper, we 
demonstrate that stimulation of cultured cells and mice 
with bacterial products containing the essential iE-DAP 
dipeptide induces innate immune responses in a Nod1-
 dependent manner.
RESULTS
Addition of peripheral structures to the core dipeptide 
recognized by Nod1 does not result in increased 
stimulatory activity
Stimulation of host cells by iE-DAP alone induces very low 
levels of IL-6 and TNFα secretion (6). Furthermore, high 
doses of iE-DAP, compared with TLR ligands, are required 
to induce chemokines in intestinal epithelial SW620 and oral 
epithelial HSC-2 cells (19, 20). The high dose of Nod1 
ligand required for Nod1 stimulation has hampered the anal-
ysis of Nod1-mediated immune responses in vitro and in 
vivo. To circumvent this problem, we sought to develop 
synthetic compounds that posses an enhanced ability to stim-
ulate Nod1. Previous reports suggest that the peripheral struc-
tures of iE-DAP–containing molecules (Fig. 1 A) aff ect 
their ability to stimulate Nod1 (6, 7). Therefore, we initially 
characterized the structural requirement for Nod1 stimula-
tory activity using a published bioassay with human embry-
onic kidney (HEK) 293T cells transiently expressing Nod1 
(6). The monomer disaccharide tetrapeptide N-acetyl-
 glucosamyl (GlcNAc)-N-acetyl-muramyl (MurNAc)-l-Ala-
γ-d-Glu-mesoDAP- d-Ala was Nod1 stimulatory, whereas 
the dimeric disaccharide tetrapeptide resulting from one 
linkage between the ε-amino residue in mesoDAP and 
the α-carboxyl residue in d-Ala was not (Fig. 1 B). We 
also found that the stimulatory activity of the tripeptide 
l-Ala-γ-d-glutaminyl-meso-DAP (iQ-DAP) was less than 
the dipeptide iQ-DAP (Fig. 1 C). These results indicate 
that NH2-terminal peptide expansion of the core dipep-
tide recognized by Nod1 does not result in higher stimula-
tory ability.
Development of synthetic compounds with high Nod1 
stimulatory activity
Based on the results given in Fig. 1, we used the dipeptide 
iE-DAP as a seed structure to develop compounds with 
an enhanced ability to stimulate Nod1. Consistent with cy-
tosolic localization of Nod1 (5), microinjection or calcium 
phosphate–mediated incorporation of Nod1 ligands into 
cells enhances the ability of the ligands to stimulate Nod1 
(6, 8, 12). Furthermore, H. pylori is reported to inject Nod1 
ligand through a type IV secretion system into host cells 
(11). These observations suggest that hydrophobic acylation 
of Nod1 ligands may improve their membrane permeability 
and ability to stimulate Nod1. To test this hypo thesis, we 
developed synthetic compounds containing various acyl 
residues at the NH2 terminus of iE-DAP (X1 in Fig. 1 A). 
N- myristoyl (C-14) iE-DAP, designated here as KF1B, 
as well as other acyl iE-DAP compounds (not depicted) 
were found to specifi cally stimulate Nod1 (Fig. 2 A), but 
not Nod2 or TLR4/MD-2, signaling using the HEK293T 
bioassay (Fig. 2 B). These results indicate that acylation 
of the iE-DAP dipeptide does not affect ligand recogni -
tion or receptor specifi city. Further analysis showed that 
KF1B exhibited a several hundredfold higher ability to 
induce Nod1-dependent NF-κB activation than the origi-
nal dipeptide iE-DAP, as determined by the amount of 
compound required for achieving 50% of maximum activ-
ity (Fig. 2 A). Testing of additional compounds revealed 
that pentadecanoyl (referred as KFC15; C-15) and pal-
mitoyl (referred as KFC16; C-16) iE-DAP also possessed 
a similar ability to stimulate Nod1 as KF1B (unpublished 
data). Although effi  cient stimulation of Nod1 by natural 
ligands requires the coexistence of calcium phosphate par-
ticles under our culture conditions (6, 8), we found that 
KF1B no longer requires calcium phosphate particles to 
stimulate Nod1 signaling, which was consistent with our 
hypothesis that the enhanced ability of KF1B to stimulate 
Nod1 is caused by increased accessibility to the cytosol 
(Fig. 2 C).
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Nod1-dependent enhancement of LPS-induced cytokine 
secretion by KF1B in macrophages and DCs
To determine if KF1B enhances LPS-induced cytokine 
 production through endogenous Nod1, human monocytic 
Mo noMac6 cells that express Nod1 were stimulated with the 
iE-DAP–derived compounds and controls. Stimulation of 
MonoMac6 cells with KF1B alone at concentrations as 
high as 2,500 ng/ml induced neither the secretion of IL-6 
nor IL-1β (Fig. 3, A and B). However, KF1B possessed a 
 high er ability to enhance LPS-induced production of these 
Figure 1. Structures of core Nod1 ligand and the effects of amino 
acid modifi cations on the Nod1 stimulatory activity. (A) Core struc-
ture of Nod1 ligands. The structure of core Nod1 ligand iE-DAP is shown 
with its peripheral residues (X1 to X4). The activity of the Nod1 ligand 
without modifi cation is given as one unit. The tripeptide in C and D 
contain L-Ala at the X1 position; KF1B, KFC15, and KFC16 have myristoyl 
[CH3(CH2)12-C=O], pentadecanoyl [CH3(CH2)13-C=O], and palmitoyl 
[CH3(CH2)14-C=O], respectively, at the X1 position. iQ-DAP has amino 
residue at the X2 position; a cross-bridge to another PGN chain occurs 
at X3. The amino residues at the X4 position varies dependent on the 
bacterial species and composition of PGN intermediates. (B) Nod1 stimu-
latory activity of purifi ed PGN fragments from B. subtilis. 105 HEK293T 
cells were transfected with the Nod1 expression plasmid together with 
NF-κB–dependent and –independent reporter plasmids as described 
previously (reference 4). 8 h after transfection, cells were treated with the 
indicated amounts of whole soluble Cellosyl-treated PGN fragments, 
Figure 2. Development of synthetic acyl Nod1 ligands. (A) En-
hanced ability of synthetic acyl compound KF1B to stimulate Nod1. 
HEK293T cells were transfected with the Nod1 expression plasmid. 8 h 
after transfection, cells were treated with the indicated amounts of the 
ligand. 24 h after transfection, NF-κB–dependent transcription activity 
was determined. (B) Nod1-dependent NF-κB activation induced by the 
acyl Nod1 ligands. HEK293T cells were transfected with the expression 
plasmid of Nod1, Nod2, or TLR4 and MD2 (TLR4/MD2) or control vector 
(−) as described in Fig. 1. 8 h after transfection, cells were treated with 
5 ng/ml KF1B, iE-DAP, AcMTP, AcAiQ, or iQ-DAP. 24 h after transfection, 
NF-κB–dependent transcription activity was determined. (C) Requirement 
of calcium phosphate particles for iE-DAP, but not KF1B, to stimulate 
Nod1. HEK293T cells were fi rst transfected with Nod1 expression plasmid 
and reporter constructs. 8 h after transfection, calcium phosphate parti-
cles were removed by changing the medium. 9 h after transfection, the 
cells were stimulated with 1 ng/ml Nod1 ligands, iE-DAP, and KF1B in the 
absence and presence of calcium phosphate particles. 24 h after transfec-
tion, NF-κB–dependent transcription activity was determined. The results 
shown in the fi gures are given as means ± SD of triplicate cultures and 
are representative of fi ve experiments.
GlcNAc-MurNAc-L-Ala-γ-D-Glu-mesoDAP-D-Ala (GM4), or dimeric 
GlcNAc-MurNAc-L-Ala-γ-D-Glu-L-mesoDAP-D-Ala cross-bridged between 
mesoDAP and D-Ala [(GM4)2]. 24 h after transfection, NF-κB–dependent 
transcription activity was determined as described previously (reference 4). 
(C) Nod1 stimulatory activity of synthetic di/tripeptides. HEK293T cells 
were transfected with the Nod1 expression plasmid (Nod1) or control 
vector (−). 8 h after transfection, cells were treated with the indicated 
amounts of synthetic iE-DAP or AiE-DAP (L-Ala-iE-DAP-D-Ala). 24 h after 
transfection, NF-κB–dependent transcription activity was determined. 
(D) Nod1 stimulatory activity of synthetic di/tripeptides. HEK293T cells 
were transfected with the Nod1 expression plasmid (Nod1) or control 
vector (−). 8 h after transfection, cells were treated with the indicated 
amounts of iQ-DAP or L-Ala-γ-D-Glu-mesoDAP-D-Ala (AiQ-DAP). 24 h 
after transfection, NF-κB–dependent transcription activity was determined. 
The results shown are given as means ± SD of triplicate cultures and are 
representative of three experiments.
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cytokines than the original iE-DAP (Fig. 3, A and B). KF1B 
was eff ective in stimulating LPS-induced responses at 
concentrations as low as 25 ng/ml and was comparable 
to MurNAc-l-Ala-γ-d-Glu-l-Lys(stearoyl)-OH (AcMTP), 
a modifi ed ligand of Nod2 (21–23). As observed with 
MonoMac6 cells, stimulation of BM-derived mouse macro-
phages and DCs with KF1B alone did not induce the secre-
tion of CCL2/MCP-1 (Fig. 3 C), IL-1β, and IL-12 (not 
depicted). However, KF1B enhanced LPS-induced CCL2 
secretion from DCs (Fig. 3 C) and IL-6 secretion from mac-
rophages (Fig. 3 D). Notably, the response of macrophages 
with KF1B was abolished in Nod1-defi cient macrophages 
(Fig. 3 D), demonstrating that KF1B requires Nod1 for en-
hancement of CCL2 secretion.
Nod1 stimulation through KF1B induces chemokine 
expression and NF-𝛋B activation in intestinal 
epithelial cells
Given that Nod1 is expressed in the intestinal epithelium, we 
tested whether KF1B alone can induce cellular responses in 
epithelial cells. We found that KF1B alone, but not meso-
DAP, Induced production of IL-8 in two human intestinal 
epithelial cell lines, LoVo and SW620 (Fig. 4, A–C). In con-
trast, LoVo cells did not respond after stimulation with LPS, 
CpG, and polyIC (Fig. 4, A and B), which was consistent 
with the lack of TLR signaling in most intestinal epithelial 
cells (17). In addition, KF1B induced NF-κB in LoVo cells 
as determined with an NF-κB–dependent reporter assay (Fig. 
4 D). ELISA, real-time PCR, and immunoblotting analyses 
showed that KF1B also induced CXCL1/Groα and CD83, 
two molecules that are important for the recruitment and 
interaction of immune cells (Fig. 4, E–G).
Nod1 and TNF-𝛂 stimulation induced common and specifi c 
gene induction in epithelial cells
To further characterize events induced by Nod1 stimulation 
in LoVo intestinal cells, we determined global gene expres-
sion changes using a cDNA microarray containing 20,000 
genes (Table I). At 60 min after stimulation, KF1B induced 
11 genes at >2-fold and 41 genes at >1.6-fold as compared 
with unstimulated cells (Table I). Further analysis at 3 and 
24 h after stimulation revealed induction of 6 and 17 genes 
at >1.6-fold levels, respectively. The intestinal epithelium is 
the fi rst line of defense against invasive bacteria and mediates 
innate immune responses, at least in part through TNFα. 
Therefore, we next examined the gene expression profi le in-
duced by KF1B and TNFα in LoVo cells. TNFα induced 37 
genes at >1.6-fold levels at 1 h after stimulation (Table I). 
Notably, 11 of these genes induced by TNFα stimulation 
were also induced by KF1B (Table I). The great majority of 
genes induced by both KF-1B and TNFα are known to be 
up-regulated through NF-κB and proinfl ammatory mole-
cules (Table I), which is consistent with the observation that 
KF1B and TNFα induce gene expression through NF-κB 
signaling. The genes induced by KF1B and TNFα included 
molecules involved in innate immune responses (CXCL1, 
MBL2, and CD83) and negative feedback regulators of in-
fl ammatory and apoptotic pathways (NFKBIA/IκBα, ATF3, 
TNFAIP3/A20, CFLAR/CLARP, and BIRC3/c-IAP2). 
Transient induction of CXCL1 mRNA in the early stage of 
Nod1 stimulation is consistent with the ability of KF1B to 
induce CXCL1 secretion (Fig. 4 E). Nod1 stimulation did 
not induce proinfl ammatory cytokines, including TNFα and 
IL-1s, suggesting that Nod1 mediates a restricted pattern of 
immune responses. The microarray results also revealed a 
Figure 3. Enhancement of LPS-induced IL-6, IL-1𝛃, and CCL2 
secretion by Nod1 stimulation in monocytic MonoMac6, macro-
phages, and DCs. MonoMac6 cells were treated with the indicated 
amounts per milliliter of compounds in the absence (−) and presence 
(+LPS) of 0.7 ng/ml E. coli O55:B5 LPS for 24 h. The levels of IL-6 (A) and 
IL-1β (B) in the medium were determined by ELISA. (C) BM-derived 
 macrophages (mϕ) were treated with 2 μg/ml KF-1B and/or E. coli 
O55:B5 LPS, and BM-derived DCs were treated with 2 μg/ml KF-1B 
and/or 10 ng/ml E. coli O55:B5 LPS for 24 h (D) BM-derived mϕ from WT 
and Nod1-defi cient (KO) mice were treated with 2 μg/ml KF-1B and/or 
10 ng/ml E. coli O55:B5 LPS for 24 h. The levels of CCL2 (C) and IL-6 
(D) in the medium were determined by ELISA. The results shown are 
given as means ± SD of triplicate cultures and are representative of 
three experiments.
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group of genes that are induced specifi cally by Nod1 or 
TNFα stimulation. 31 genes were induced by Nod1 but not 
TNFα stimulation. These genes included signaling molecules 
of TLR and IL1R pathways (MAP3K7/TAK1 and MAIL/
Iκ-Bζ), components of ubiquitin/proteasome pathway 
(UBE2M, UBE2D3, RYBP, and WSB1) and 6 novel genes, 
whereas TNFα stimulation induced 37 unique genes in-
cluding signaling molecules of Ephrin pathways (EFNA1
and EPHA2), transcription factors (EGR1, FOSL2/Fra2, and 
ELF3), and innate immune factors (PLAU/plasminogen acti-
vator and TNFAIP2a; Table I). These results suggest that 
Nod1 and TNFα mediate unique and overlapping innateim-
mune responses in epithelial cells.
Nod1 stimulation induces chemokine production 
and neutrophil recruitment in vivo
To test whether KF1B mediates Nod1-dependent immune 
responses in vivo, we stimulated WT and Nod1-defi cient 
mice with KF1B i.p. and measured production of chemo-
kines and cytokines in the animals. Administration of KF1B 
induced rapid production of CCL2 (Fig. 5 A) and CXCL2/
Groβ in the serum (Fig. 5 B). KF1B was as eff ective as LPS 
or MDP in inducing secretion of CCL2 (Fig. 5 A). Notably, 
serum secretion of CCL2 in response to KF1B was abolished 
in Nod1-defi cient mice (Fig. 5 A), indicating that production 
of CCL2 is totally dependent on Nod1 in vivo. The lack of 
response of Nod1-defi cient mice was specifi c in that they 
produced CCL2 after administration of LPS or MDP (Fig. 
5 A). Because Nod1 is highly expressed in airways and the 
intestine (5), we also tested whether intranasal and oral ad-
ministration of KF1B could induce immune responses. Con-
sistent with the expression of Nod1 in these organs, production 
of CCL2 was induced in WT mice but not in Nod1-defi -
cient mice after intranasal and oral administration of mice 
with KF1B (Fig. 5 C). In contrast to the production of che-
mokines, administration of KF1B did not induce secretion 
of IFN-γ, IL-3, CSF2 (M-CSF), IL-12 (Fig. 5 D), and IL-4, 
-10, -18, and -1β (not depicted) in the serum or tissues, in-
cluding spleen, liver, and kidney, when compared with the 
levels found in control mice (Fig. 5 D). Further analysis did 
not reveal any production of these cytokines at 24 h after 
Nod1 stimulation (unpublished data), suggesting that the lack 
of response is not caused by delayed production of these cy-
tokines. These fi ndings are consistent with our results in vitro 
that Nod1 stimulation induces a restricted number of im-
mune response genes. Because Nod1 stimulation induced 
chemokine secretion in vitro and in vivo, we next tested 
whether Nod1 stimulation can induce recruitment of specifi c 
Figure 4. Cytokine secretion from human intestinal epithelial 
LoVo cells. LoVo cells were treated with 2 μg/ml of each ligand, except 
200 ng/ml for AcMTP and 10 ng/ml TNFα. The levels of IL-8 (A) and CXCL1 
(E) were determined by ELISA. (B) LoVo cells were treated with 20 μg/ml 
KF1B, 5 μg/ml AcMTP, 1 μM CpG, 5 μg/ml polyIC, and 5 μg/ml E. coli 
O55:B5 LPS. The levels of IL-8 in medium at the indicated times were 
determined by ELISA. (C) SW620 cells were treated with 5 μg/ml of 
the indicated ligands. The secretion levels of IL-8 were determined by 
ELISA. (D) LoVo cells were treated transfected with NF-κB–dependent 
and –independent reporter by Lipofectamine 2000. 8 h after transfection, 
cells were treated with 2,000 ng/ml KF1B, iE-DAP, or control mesoDAP or 
left untreated (−). (F) The mRNA levels of CD83, NFKBIA, IL-8, and CXCL1 
from cells treated with 2 μg/ml KF1B (closed bars) for 60 min or left 
untreated (open bars) were determined by real-time PCR analysis. 
(G) CD83 in lysates from LoVo cells treated with 2,000 ng/ml KF1B for 
24 h was detected by immunoblotting with anti-CD83 antibody. 
The results shown are given as means ± SD of triplicate cultures
and were representative of fi ve experiments.
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Table I. Genes induced by Nod1 and TNFα stimulation
KF1B (1 h) TNF𝛂 (1 h) KF1B (3 h) KF1B (24 h)
Gene Fold Gene Fold Gene Fold Gene Fold
NFKBIA 3.45 NFKBIA 10.53 BIRC3 3.28 P4HA1 2.02
CXCL1 2.67 CLTCL1 5.37 NFKBIA 3.00 Novel 1.92
CFLAR 2.42 TNFAIP3 5.12 CD83 1.96 BNIP3L 1.91
SKI 2.25 CXCL1 4.68 TNFAIP3 1.85 Novel 1.90
HNRPC 2.25 Unknown 4.35 MBL2 1.78 HSD11B2 1.85
NUP43 2.13 MBL2 4.24 VPS13A 1.62 ANGPTL4 1.84
AHCYL1 2.04 BIRC3 4.07 DDIT4 1.82
HIPK3 2.04 SKI 3.98 ANGPTL4 1.81
ATF3 2.03 MCF2 3.51 WSB1 1.76
RYBP 2.02 Novel 2.92 GBE1 1.76
TCERG1 2.00 ELF3 2.92 WSB1 1.75
H3F3B 1.97 EFNA1 2.92 ELK3 1.74
Novel 1.93 CD83 2.75 EGLN1 1.73
RNF32 1.86 TNFAIP3 2.69 PLOD2 1.69
WSB1 1.85 JUN 2.44 ADM 1.68
WSB1 1.82 Novel 2.40 CYLN2 1.67
PRDX3 1.81 PLAU 2.33 PIM1 1.62
CXCL1 1.79 TNFAIP2 2.31 SERPINB1 1.62
MAIL 1.78 EFNA1 2.29
Novel 1.76 Novel 2.28
DC36 1.76 CFLAR 2.27
JUN 1.75 PDGFB 2.26
Novel 1.75 PLK3 1.93
RAP2A 1.73 EPHA2 1.89
MAP3K7 1.73 TIEG 1.85
UBE2M 1.73 EGR1 1.85
PHLDA1 1.71 SF1 1.82
NCK1 1.70 IFNGR2 1.81
STK17A 1.70 BIRC1 1.79
SEC23A 1.70 Novel 1.76
DDX18 1.70 DUSP5 1.73
CCDC6 1.69 ARRDC3 1.71
RAGE 1.69 VMP1 1.71
Novel 1.69 CXCL1 1.71
PCF11 1.69 Novel 1.69
Novel 1.69 MAP3K8 1.67
ETEA 1.68 Novel 1.65
NFS1 1.67 ATF3 1.64
PPA2 1.67 FOSL2 1.64
UBE2D3 1.67 EGR1 1.61
Novel 1.66 Novel 1.60
Novel 1.65
LoVo cells were treated with 2 μg/ml KF1B and 10 ng/ml TNFα for indicated times. Genes induced by KF1B at >1.6-fold ratio between control and treated cells are shown. 
The genes that were commonly induced by Nod1 and TNFα stimulation and those that are known to be induced by NF-κB, proinfl ammatory TNFα, and/or LPS (46) are 
underlined and bolded, respectively.
types of immune cells into the peritoneal cavity after i.p. ad-
ministration of the synthetic Nod1 ligand. 16 h after adminis-
tration, Nod1 stimulation was found to induce recruitment of 
Gr1+ neutrophils but not lymphocytes, macrophages, or other 
cell types as determined by morphological (Fig. 6, A and B) 
and fl ow cytometric analyses (Fig. 6 C). The eff ect was Nod1 
dependent in that the recruitment of neutrophils induced 
by KF1B was abolished in Nod1-defi cient mice (Fig. 6). 
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FK1B did not increase the number of macrophages or lym-
phocytes in the peritoneal cavity (Fig. 6 B). The recruitment 
of neutrophils mediated through Nod1 stimulation is consis-
tent with the induction of CXCLs by KF1B. To determine 
whether resident cells found in the peritoneal cavity respond 
to KF1B, we prepared intraperitoneal cells and stimulated 
them with the Nod1 ligand. We found no detectable secre-
tion of CXCL1 after stimulation of KF1B even though the 
cells responded to LPS (Fig. 6 E). Notably, analysis of perito-
neal cavity tissues that are rich in mesothelial cells revealed 
induction of CXCL1 expression after KF1B stimulation in 
vivo (Fig. 6 F). These results suggest that mesothelial cells 
and/or other cells present in the tissue from the peritoneal 
cavity are the main sources of CXCL1.
DISCUSSION
We previously demonstrated that Nod1 is essential for host 
response against iE-DAP–containing small molecules (5). 
These iE-DAP–containing molecules include intermediates 
and degradation products of PGN (5, 6, 12). In this paper, we 
show that the monomeric disaccharide tetrapeptide was Nod1 
stimulatory, whereas the dimeric disaccharide tetrapeptide 
 resulting from one linkage between the ε-amino residue in 
mesoDAP and the α-carboxyl residue in d-Ala was not. This 
linkage bond is important for the cross-linking among PGN 
chains (24). The percentage of linked/free PGN chains varies 
among bacterial species and growth conditions in certain bac-
teria (24). For example, 80% of the ε-amino acid residue of 
DAP remains free in Escherichia coli (24). Thus, our fi nding 
that cross-linking between DAP and d-Ala eliminates Nod1-
mediated host recognition suggests that the ability of bacte -
rial PGN fragments to stimulate Nod1 varies depending on 
species and growth conditions of bacteria. Both hosts and 
bacteria have amidases that cleave the bond between the 
polysaccharide and oligopeptide chains of PGN, and bacteria 
also have enzymes that generate various oligopeptide species 
during the synthesis and remodeling of PGN (23). A tripep-
tide l-Ala-iE-DAP was reported to possess a higher ability to 
stimulate Nod1 than dipeptide iE-DAP using purifi ed frac-
tions (7). We confi rmed the latter result by comparing the 
Nod1 stimulatory activity of l-Ala-iE-DAP and iE-DAP us-
ing synthetic equivalents (Fig. 2 C). However, we found that 
the stimulatory activity of the tripeptide l-Ala-iQ-DAP was 
less than that elicited by the dipeptide iQ-DAP (Fig. 2 D). 
Therefore, the association between NH2-terminal extension 
of the core structure and increased ability to stimulate Nod1 
is not a general feature of Nod1 ligands.
Bacterial- and synthetic iE-DAP–containing molecules 
are known to induce innate and acquired immune responses 
(25). However, because of the relatively poor immunostimu-
latory ability of iE-DAP–containing molecules, compared 
with that of LPS and MDP-related molecules (see Fig. 4 D) 
(6, 19, 20), it has been diffi  cult to investigate the role of Nod1 
stimulation in immune responses. In this paper we developed 
acyl compounds that possess an enhanced ability to stimulate 
Nod1. These molecules, including myristoyl (C-14), pen-
tadecanoyl (C-15), and palmitoyl (C-16) iE-DAP compounds 
(referred to as KF1B, KFC15, and KFC16, respectively), 
were found to exhibit a several hundredfold stronger ability 
to stimulate Nod1 than the original iE-DAP. Because these 
fatty acyl residues naturally exist in host membrane lipids, their 
potent stimulatory ability could be explained by increased 
translocation across the plasma membrane and delivery into 
the cytosol through cellular machinery that may include lipid 
fl ippases or related factors (26). Using these compounds, we 
investigated the immune response induced upon Nod1 stim-
ulation. We found that intestinal epithelial cell lines were 
highly responsive, whereas macrophages, DCs, and spleno-
cytes did not respond to Nod1 ligands alone under our 
experimental conditions. These results are consistent with 
the tissue expression profi le of Nod1 that showed high levels 
of Nod1 expression in epithelial tissues such as the intestine 
(5). Several genes induced by Nod1 stimulation, including 
CXCL1, CD83, and MBL2, are known to be involved in the 
recruitment of immune cells and complement factors after 
bacterial infection. Similarly, our analysis in mice revealed 
that secretion of CCL2 was induced in serum and multiple 
tissues upon Nod1 stimulation in vivo. These results suggest 
that Nod1 functions as a pathogen recognition receptor to 
induce expression of proteins that play a critical role in the 
early stages of the innate immune response.
Nod1 is an intracellular protein, and, thus, recognition 
of bacteria through Nod1 would signal potentially harmful 
invasion of epithelial surfaces such as that lining the gut. In 
the case of the intestine, the mucosa is exposed to a large 
concentration of commensal bacteria that express a wide ar-
ray of TLR ligands. However, inappropriate innate recogni-
tion and infl ammatory responses are avoided, at least in part, 
by the lack of TLR signaling in the surface intestinal epithe-
lium (17). A model suggested by these results is that after in-
vasion of the epithelium by pathogenic bacteria, TLR-positive 
innate immune cells are recruited, though Nod1-induced 
chemokines and stimulation of these cells results in the pro-
duction of cytokines such as TNFα that amplify the host 
response. Thus, although both TLR and Nod proteins rec-
ognize  bacterial products, they may play distinct roles in bac-
terial clearance. Intestinal epithelial cells are also likely to play 
an important role in this amplifi cation loop of the host 
defense through the induction of genes that are unique to 
TNFα  signaling. Comprehensive microarray analysis re-
vealed that Nod1 and TNFα induced a diff erent profi le of 
gene ex pression that include both common and specifi c 
genes in epi thelial cells. These observations suggest that pri-
mary and secondary responses against bacteria in intestinal 
epithelial cells are diff erent. The genes induced by Nod1, but 
not TNFα, include TAK1 and Iκ-Bζ, which are critical fac-
tors in TLR and IL-1R pathways (27–29). Co-stimulation 
with Nod1 and Nod2 enhances TLR signaling (6, 30). The 
enhancement of TLR signaling by Nod1 might be due, at 
least in part, to the induction of TAK1 and Iκ-Bζ. Nod1 
stimulation also induced several novel genes that have un-
known functions. Further studies are required to reveal the 
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physiological role of these Nod1-responsible genes. The mo-
lecular basis that accounts for the induction of unique genes 
by Nod1 and TNFα signaling is unclear. A possible explana-
tion is that diff erences in gene expression refl ect diff erential 
activation of intracellular signaling molecules. For example, 
RICK, a downstream factor of Nod1, has been shown to 
activate NF-kB through TRAF6, whereas TRAF2 is critical 
for TNFα signaling (31–33).
Nod1 gene variants have been recently associated with 
the development of asthma (34). Moreover, genetic varia-
tions in Nod1 and Nod2 are associated with increased 
 susceptibility to Crohn’s disease (35–37). The Crohn’s 
disease–associated Nod2 mutations are defective in their 
response to muramyl dipeptide (38, 39). Because both Nod1 
and Nod2 share the same downstream components for 
signaling, the defective response observed in cells harboring 
Nod2 mutations could be rescued by Nod1 stimulation. Thus, 
ligands such as KF1B could be useful for the development 
of novel approaches to treat Nod1- and Nod2-associated in-
fl ammatory diseases.
Figure 5. Nod1-dependent CCL2 induction in vivo. (A) WT and 
Nod1-defi cient mice were administrated i.p. with 200 μg KF1B, iE-DAP, 
MDP, E. coli O55:B5 LPS, or PBS alone. The serum level of CCL2 was 
determined by ELISA. Because the relative levels of CCL2 induced by 
MDP was lower than those by KF1B, the CCL2 levels induced by MDP 
are also given (inset). The CCL2 levels are given with means ± SD from 
three mice. (B) The serum CXCL2 level from mice stimulated with 
50 μg KF1B or PBS alone at indicated times after i.p. injection was 
determined by ELISA. Representative data from three independent 
experiments are shown. (C) The serum levels of CCL2 from WT and 
Nod1-defi cient (KO) mice treated with 50 μg by a different administra-
tion method (i.n. [intranasal], i.p., and oral route) at 6 and 24 h were 
determined by ELISA. Representative data from four independent 
experiments are shown. (D) cytokine levels in tissues from mice stimu-
lated with 200 μg KF1B or PBS alone (−) 6 h after i.p. injection was 
determined by ELISA. Representative data from three independent 
experiments are shown. The results are representative of at least 
three experiments.
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MATERIALS AND METHODS
Bioassay for Nod1 ligand activity. Ligand-dependent NF-κB activation 
was determined using HEK293T cells transiently expressing Nod1, Nod2, 
or TLR4 and MD2 in the presence of pBxIV-luc and pEF1BOS-β-gal as 
described previously (6). In brief, HEK293T cells were transfected with ex-
pression plasmids by the calcium phosphate method, and cells were treated 
with medium containing various ligands 8 h after transfection. 24 h after 
transfection, ligand-dependent NF-κB activation was determined with a 
reporter assay. LoVo cells were transfected with pBxIV-luc and pEF1-BOS-
β-gal (4) by Lipofectamine 2000 (Invitrogen), and cells were treated with 
medium containing 2 μg/ml KF1B, 0.2 μg/ml AcMTP, or 10 ng/ml TNFα 
3 h after transfection. 24 h after transfection, ligand-dependent NF-κB acti-
vation was determined with a reporter assay.
Other materials. Highly purifi ed fractions of whole soluble Cellosyl-treated 
PGN fragments (GlcNAc-MurNAc-l-Ala-γ-d-Glu-mesoDAP-d-Ala, shown 
as fraction 3 in reference 31, or dimeric GlcNAc-MurNAc-l-Ala-γ-d-Glu-
l-mesoDAP-d-Ala cross-bridged between mesoDAP and d-Ala, shown as 
fraction 21 in reference 41) from Bacillus subtilis were prepared as described 
previously (41). In brief, dibenzyl-2,6-diaminopimelate (dibenzyl-DAP) 
was fi rst connected to 2-chlorotrityl resin, and the remaining amino group 
of DAP was reacted with Fmoc-d-Glu-OBn. After deprotection of Fmoc 
group, the acyl group (C-14, C-15, or C-16) was introduced to the liber-
ated amino group to give the corresponding acylated iE-DAP on the resin. 
After cleavage from the resin with 10% trifl uoroacetic acid, cleavage of 
the remaining protecting groups gave KF1B, KFC15, or KFC16, respec -
tive ly. Synthetic compounds iE-DAP, iQ-DAP, CpG, and polyIC were de-
scribed previously (5). Synthetic Ac-(6-O-stearoyl)-MurNAc-l-Ala-γ-d-Glu 
(AcMDP), AcMTP, and d-Ala-Gln-octadecyl ester (AcAiQ) were obtained 
from Bachem. E. coli O55:B5 LPS was purchased from Sigma-Aldrich. The 
LPS preparation that lacked contamination of substantial Nod1 and Nod2 
stimulatory activity in the HEK293T bioassay was used in this study.
Cytokine assay. Human LoVo, SW620, and MonoMac6 cells were cul-
tured and maintained in RPMI 1640 medium (Invitrogen). Macrophages 
and DCs were derived from BM using CSF1 and CSF2, respectively, as pre-
viously described (29). Cells were treated with the indicated amounts per 
milliliter of various ligands for the times shown in the fi gure legends. The 
cytokine and chemokine levels were determined by sandwich ELISA kits 
using specifi c antibodies (R&D Systems).
In vivo induction of cytokines and immune cell recruitment. 8-wk-
old C57BL/6 (B6) WT and Nod1−/− mice in B6 background were main-
tained at the University of Michigan Animal Facility. B6 background 
Nod1−/− mice used in this study were generated by backcrossing at least six 
times with the parental B6 strain. Mice were administrated with the indicated 
amounts of various ligands by routes described in the fi gure legends. At the 
times indicated in the fi gures, sera and organs were collected from killed mice, 
and homogenates of organs were prepared by sonication with PBS (Invi-
trogen) containing 1% Triton X-100 and a mixture of protease inhibitors 
(Sigma-Aldrich), followed centrifugation at 100,000 g for 10 min. The cyto-
kine and chemokine levels in sera and tissue homogenates from mice were 
determined by ELISA. For recruitment of immune cells at 24 h after i.p. 
administration of KF1B, peritoneal cells were collected from killed mice by 
PBS lavage. After centrifugation (Cytospin 2; Shandon Ltd.), cells were fi xed 
and stained with a staining kit (Diff ; Dade Behring Inc.) according to the 
manufacturer’s recommendations. Cell types were determined by standard 
morphological features of stained cells. The number of GR1+ cells in 105 cells 
was determined by fl ow cytometry (FACScan II; BD Biosciences) as pre-
viously described (41). The mouse studies were approved by the University 
of Michigan Committee on the Use and Care of Animals. For estimation of 
CXCL1 mRNA, total RNA was isolated from peritoneal tissue of WT mice 
using Trizol (Invitrogen). In brief, several 1-cm2 fragments of the peritoneal 
membrane were isolated and immediately homogenized with Trizol solution 
with and without KF1B stimulation. To assess mRNA expression, a semi-
quantitative RT-PCR method was used, as previously described (42). CXCL1 
and control GAPDH gene fragments (355 and 191 bp, respectively) were 
amplifi ed by 35 cycles of the PCR with 94°C for 1 min, 60°C for 1 min, and 
72°C for 1 min using gene-specifi c primers (CXCL1, 5′-C A C C T C A A G A A-
C A T C C A G A G C T -3′ and 5′-C A A G C A G A A C T G A A C T A C C A T C G -3′; 
GAPDH, A A C G A C C C C T T C A T T G A C -3′ and 5′-C C A C G A C A T A C T-
C A G C A C -3′) and subjected to 2% agarose electrophoresis.
Gene microarray analysis. LoVo cells were treated with 2 μg/ml KF1B, 
AcMTP, 10 ng/ml TNFα, or left alone for the times indicated in the fi gures. 
Total RNA was prepared, and Cy3- and Cy5-labeled cDNA was synthe-
sized from total RNA as described previously (43). Diff erential expression of 
20,000 human genes (Invitrogen) was determined by hybridization of the 
probes with their cDNAs, followed by an analysis using a microarray scanner 
(GenePix 4000A; Molecular Devices) as described previously (43).
Real-time PCR and immunoblotting analysis of ligand-induced 
gene profi ling change. Quantitative real-time PCR was performed using 
gene-specifi c primers (CD83, 5′-T T T A A T G G C C G G C T G G A A A T G -3′ 
Figure 6. Specifi c recruitment of neutrophils by Nod1 stimulation. 
WT and Nod1-defi cient mice were i.p. administrated with 50 μg KF1B or 
control PBS. 24 h after injection, i.p. fl uid was obtained and analyzed by 
morphological assay after Diff staining. (A) The randomly chosen repre-
sentative views of i.p. cells from WT mice injected with PBS and KF1B and 
from Nod1-defi cient (KO) mice injected with KF1B are shown. (B) The 
numbers of neutrophils (NEU), macrophages (MN), lymphocytes (LYM), 
and other cell types (OC) were counted and given as means ± SD from 
independent experiments using three mice. (C) The numbers of GR1+ cells 
from WT and Nod1-defi cient (KO) mice with KF1B were determined by 
fl ow cytometry. (D) In vitro secretion of CXCL1 from i.p. cells. The i.p. cells 
from WT mice were stimulated with 50 μg/ml KF1B, control LPS, or left 
alone for 24 h. CXCL1 levels were determined by ELISA. (E) Induction of 
CXCL1 mRNA in peritoneal tissue. Tissue from the peritoneal membrane 
was isolated from WT mice 1 h after stimulation by i.p. injection of PBS 
(−) or 50 μg KF1B. The CXCL1 and control GADPH mRNA were detected 
by RT-PCR. The results are representative of three experiments.
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and 5′-T T T A G C C C A T G C A A C A G C C T T G T G -3′; NFKBIA, 5′-C G-
C G A C G G G C T G A A G A A G G -3′ and 5′-A T G G C C A A G T G C A G G A A-
C G A G -3′; IL8, 5′-C A A G G G C C A A G A G A A T A T C C G A A C T -3′ and 
5′-T A T C A C A T T C T A G C A A A C C C A T T C A A -3′; and CXCL1, 5′-C T C-
A A T C C T G C A T C C C C C A T A G T T A -3′ and 5′-G T G G C C T C T G C A G C-
T G T G T C T C T -3′) and SYBR green dye with a real-time PCR system 
(model 7300; Applied Biosystems) as previously described (44, 45). The 
mean calculated quantity of the target gene for each sample was then di-
vided by the mean calculated quantity of the housekeeping genes GAPDH 
and HMBS corresponding to each sample to give a relative expression of the 
target gene for the sample (46). All reactions were performed in duplicate. 
Immunoblotting analysis of CD83 in 50 μg total protein lysate from cells 
treated with 2 μg/ml KF1B, AcMTP or left alone was performed using 
anti-CD83 monoclonal antibody (BD Biosciences). Equal loading of pro-
teins were confi rmed by reversible staining with Ponceau S (Sigma-Aldrich) 
before immunodetection.
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